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Abstract
The objective of the research was to study the possible association between MALAT1 gene rs3200401 poly-
morphism and the survival of patients with bladder cancer and clinicopathological characteristics in bladder
cancer.
Materials and Methods. The venous blood of 141 patients with transitional cell carcinoma of the urinary
bladder was used for study. Genotyping of MALAT1 gene rs3200401 polymorphism was performed by real-time
polymerase chain reaction using the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA)
and Taq-Man Assays (TaqMan©SNP Assay C 3246069 10). Statistical analysis was performed using the SPSS
software package (version 17.0). The Kaplan-Meier estimator and Cox regression were used to check the
possible association between MALAT1 rs3200401-genotypes and the age of transitional cell carcinoma of the
urinary bladder onset. P values < 0.05 were considered as statistically significant.
Results. The obtained results revealed that hemoglobin concentration was lower in patients with transitional
cell carcinoma of the urinary bladder and rs3200401TT-genotype than in patients with rs3200401CC-genotype
(p = 0.024). Herewith, fasting glucose, creatinine concentration, and tumor width were significantly higher
in patients with transitional cell carcinoma of the urinary bladder and rs3200401TT-genotype as compared
to rs3200401CC-genotype carriers (p = 0.036, p = 0.039, p = 0.028, respectively). The results of survival
analysis demonstrated that transitional cell carcinoma of the urinary bladder occurred much later in persons
with rs3200401TT-genotype as compared to rs3200401C-allele carriers (log rank p = 0.016), and the risk of
transitional cell carcinoma of the urinary bladder onset was lower in individuals with rs3200401TT than in major
rs3200401C C-allele carriers (hazard ratio = 0.413; p = 0.047).
Conclusions. Rs3200401 polymorphism of MALAT1 gene is associated with disease-free survival in Ukrainian
patients with transitional cell carcinoma of the urinary bladder. Transitional cell carcinoma of the urinary bladder
occurs later in persons with rs3200401TT-genotype than in individuals with rs3200401CC- and rs3200401CT-
genotypes.
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Problem statement and analysis of
the latest research
Metastasis-associated lung adenocarcinoma tran-
script 1 (MALAT1) also known as non-coding nuclear-
enriched abundant transcript 2 (NEAT2) is highly
conserved long non-coding RNA (lncRNA) that is
actively expressed in various human cells and tis-
sues (kidney, brain, heart, thyroid gland, adrenal
glands, skeletal muscles, ovaries, intestines, lungs,
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liver, prostate, etc.) [1]. The MALAT1 gene tran-
script was first described in 1997 as an alpha tran-
script in patients with multiple endocrine neopla-
sia type 1 (MEN-1) [2]. In 2003, MALAT1 was
identified as a transcript associated with metasta-
sis in patients with early-stage non-small cell lung
cancer [3]. Today, the main MALAT1 function is
thought to be the regulation of metastasis-related
genes expression [4]. In addition, its important role
in cellular processes such as alternative splicing,
nuclear organization, and epigenetic modulation of
gene expression has been proven [5].
In 2012, MALAT1 overexpression in bladder
cancer (BC) cells was revealed by Ying et al. [6].
Researchers also showed that level of MALAT1
production in primary BC tumors of patients with
metastases was significantly higher as compared
to tumors of patients without metastases. Along
with this, Xie et al. have recently demonstrated
that lncRNA MALAT1 suppresses apoptosis of ma-
lignant bladder cells and promotes their invasion
through miR-125b inactivation [7].
Li et al. have established the link between
MALAT1 expression level on the one hand and
the degree of BC cell differentiation, the stage of
cancer and the presence of distant metastases on
the other hand [8]. In addition, researchers have
shown that overall survival in BC patients with high
MALAT1 expression was much lower than in BC
patients with low MALAT1 production. Zhan el. re-
vealed that excessive MALAT1 expression reduced
the time of recurrence development in post-operated
BC patients [9]. However, no relationship between
MALAT1 expression level and morphological char-
acteristics of malignant bladder tumor has been
found.
Today, there are several studies on the associa-
tion between MALAT1 genetic polymorphism and
malignant tumors emergence and development [10,
11]. However, there are no studies devoted to analy-
sis of association between MALAT1 gene polymor-
phic sites and BC risk, different BC tumor charac-
teristics, and BC patient survival.
The objective of the research was to study
the possible association between MALAT1 gene
rs3200401 polymorphism and the survival of BC
patients and clinicopathological characteristics in
BC.
1. Materials and Methods
The venous blood of 141 patients with transitional
cell carcinoma of the urinary bladder (TCCUB)
(mean age [ ± SD] 67.60 ± 12.12 years) was used
for study. All patients were treated at Sumy Re-
gional Clinical Oncology Hospital from 2005 to
2016. The final morphological diagnosis of TC-
CUB was made in accordance with the European
Association of Urology (EAU) Guidelines (2016)
[12, 13]. All patients had stage II cancer according
to the Tumour-Node-Metastasis (TNM) classifica-
tion of malignant tumors (8th edition, 2017) [14],
which was established by histological examination
or Magnetic Resonance Imaging (MRI) results. Per-
sons with hereditary pathologies, diseases of un-
known etiology, and tumors of other localization
were excluded from the study.
The study was conducted in compliance with
the Council of Europe Convention for the Protec-
tion of Human Rights and Biomedicine, the Dec-
laration of Helsinki, and the Order of the Ministry
of Health of Ukraine No 690 (23.09.2009). All par-
ticipants signed the informed consent for genetic
testing. The study protocol was approved by the
Ethic Committee of the Medical Institute of Sumy
State University (No 3/05.12.11).
Whole venous blood was collected into 2.7 ml
Monovette tubes with addition of EDTA (Sarst-
edt, Germany). DNA was extracted from venous
blood leukocytes using commercial Thermo Scien-
tific GeneJET Whole Blood Genomic DNA Purifi-
cation Mini Kit (USA).
Genotyping of MALAT1 gene rs3200401 poly-
morphism was performed by a real-time polymerase
chain reaction (Real-Time PCR) using 7500 Fast
Real-Time PCR System (Applied Biosystems, Fos-
ter City, USA) and Taq-Man Assays (TaqMan©SNP
Assay C 3246069 10). The amplification reaction
consisted of 50 cycles: initial denaturation – 95◦C
(20 s), denaturation – 95◦C (30 s) hybridization and
elongation – 60.0◦C (30 s). Analysis of obtained
data was performed using the 7500 Fast Real-Time
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Table 1. Clinicopathological characteristics of TCCUB patients with different MALAT1 rs3200401
genotypes.
Parameter
Genotype
pCC CT TT
(n = 106) (n = 29) (n = 6)
Blood analysis
Hb, (g/l) 131.1 ± 21.9 124.0 ± 21.5 106.3 ± 23.9 0.014
WBC, (109/l) 7.2 ± 2.4 6.2 ± 1.9 8.2 ± 1.9 0.056
ESR, (mm/h) 14.7 ± 11.2 20.0 ± 15.7 23.3 ± 30.6 0.075
Fasting glucose, (mmol/l) 5.4 ± 1.5 5.5 ± 1.5 7.1 ± 2.3 0.043
Creatinine, (µmol/l) 83.8 ± 18.5 90.0 ± 20.4 104.5 ± 33.8 0.022
Tumor morphology
Tumor length, (sm) 3.2 ± 1.1 3.4 ± 1.2 3.5 ± 1.5 0.780
Tumor width, (sm) 2.9 ± 1.1 3.1 ± 1.2 4.2 ± 1.7 0.027
Tumor height, (sm) 3.3 ± 1.0 3.2 ± 1.0 3.9 ± 1.2 0.283
Tumor volume, (sm3) 38.2 ± 36.7 42.8 ± 34.3 74.4 ± 72.4 0.076
Notes: Hb – hemoglobin; WBC – white blood cells; ESR – erythrocyte sedimentation rate; n – number of
patients.
PCR Software.
Statistical analysis was performed using the
SPSS software package (version 17.0). Continu-
ous data are presented as mean ± SD; nominal
data are presented as quantitative and percent val-
ues. All continuous variables were normally dis-
tributed (the Shapiro-Wilk test). To check the devi-
ation of MALAT1 rs3200401-genotypes distribution
from the Hardy-Weinberg equilibrium, the Pear-
son’s χ 2 criterion was used. The significance
of mean value differences in groups with differ-
ent rs3200401-genotypes was determined using the
one-way analysis of variance (ANOVA), followed
by the Bonferroni correction. The Kaplan-Meier es-
timator and Cox regression were used to check the
possible association between MALAT1 rs3200401-
genotypes and the age of TCCUB onset. Cox re-
gression was performed under dominant, super-
dominant, and recessive models of inheritance, both
without adjustment, and after adjustment for age,
gender, body mass index, metastases, smoking habits,
and alcohol abuse. All tests were two-sided, p val-
ues < 0.05 were considered as statistically signifi-
cant.
2. Results
MALAT1 gene rs3200401 polymorphism genotyp-
ing revealed that the ratio of CC-homozygotes, CT-
heterozygotes and TT-homozygotes in TCCUB pa-
tients was 75.2%, 20.6% and 4.3%, respectively.
The distribution mentioned above (minor T-allele
frequency – 0.15) did not deviate from the Hardy-
Weinberg equilibrium (p = 0.143).
The results analyzing the association between
of MALAT1 gene rs3200401 polymorphic site and
some laboratory parameters in TCCUB patients
and tumor morphological characteristics are pre-
sented in Table 1. Significant association was es-
tablished for hemoglobin (p = 0.014), fasting glu-
cose (p = 0.043), creatinine (p = 0.022), and tu-
mor width (p = 0.027). Analysis using the Bon-
ferroni correction showed that hemoglobin con-
centration was significantly lower in persons with
TT-genotype than in individuals with CC-genotype
(p = 0.024); herewith, fasting glucose, creatinine
concentration, and tumor width were significantly
higher in TTCUB patients with TT-genotype as
compared to CC-genotype carriers (p = 0.036,
p = 0.039, p = 0.028, respectively).
The next step of our study was to analyze the
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possible association between MALAT1 gene
rs3200401 polymorphism and the age of TCCUB
onset. The mean age of TCCUB onset depending
on rs3200401-genotypes is shown in Table 2. Fig.
1 shows the Kaplan-Meier curve for cancer-free sur-
vival analysis depending on MALAT1 rs3200401-
genotypes according to the additive model. It is
demonstrated that TCCUB occurred much later in
persons with TT-genotype as compared to carriers
of CC- and CT-genotypes (log rank p = 0.016).
Table 2. BC-free survival analysis depending on
MALAT1 rs3200401 genotypes.
Geno-
type
n
Mean
age
SE 95 % CI
log
rank
p
CC 106 61.8 1.3 59.2-64.4
0.016CT 29 66.1 1.7 62.9-69.4
TT 6 77.3 3.4 70.7-84.0
Notes: : SD – standard error; 95 % CI – 95 %
confidence interval.
The results of Cox regression analysis are shown
in Table 3. TCCUB risk was found to be signifi-
cantly lower in individuals with TT genotype than in
major C-allele carriers (hazard ratio (HR) = 0.343;
p = 0.012). The results were maintained after ad-
justing for age, sex, body mass index, metastases,
smoking habits, and alcohol abuse (HR = 0.413;
p = 0.047).
3. Discussion
MALAT1 gene is located on chromosome 11
(11q13.1), contains 8, 708 base pairs and includes
2 exons [9]. Today, 5, 730 single-nucleotide poly-
morphisms (SNP) of MALAT1 gene are known [15].
One of the most studied in the context of cancer
development is rs3200401 locus.
The essence of rs3200401 SNP of MALAT1
gene is the replacement of cytosine to thymine at
65504361 position of chromosome 11. Experimen-
tal results have shown that such nucleotide substi-
tution causes the increase in MALAT1 molecule
minimum free energy, which, in turn, alters its
spatial structure and impairs its interaction with
serine/arginine-rich splicing factor SC35 [11]. The
impairment of interaction between MALAT1 and
SC35 results in the inhibition of pre-mRNA splic-
ing and the expression of genes involved in tumor
metastasis.
The results of our study showed that MALAT1
gene rs3200401 polymorphic site is associated with
disease-free survival in patients with TCCUB. BC
has been shown to occur much later in individuals
with TT-genotype as compared to major C-allele
carriers. Similar data were obtained by
Wang et al. [11]. Researchers have shown that lung
cancer patients with rs3200401CT- and
rs3200401TT-genotypes had significantly longer
median survival time than patients with CC-geno-
type. Along with this, Peng et al. have revealed
that women with rs3200401CT-genotype had sig-
nificantly lower risk of breast cancer development
as compared to CC-homozygotes [10].
In addition, our study found that rs3200401TT
genotype was associated with low hemoglobin con-
tent and high creatinine and fasting glucose con-
centrations as compared to rs3200401CC genotype.
There may be molecular mechanism which can ex-
plained such negative effect of rs3200401T-allele.
At least, Wang et al. have shown that, in contrast to
protective effect on malignant tumor development,
the rs3200401T- allele is a part of haplotype that
increases coronary heart disease risk in Chinese
population [16].
Moreover, we found that tumor width was sig-
nificantly larger in rs3200401TT-heterozygotes than
in rs3200401CC-homozygote. This may be the re-
sult of small amount of data being analyzed. Here-
with, no relation between rs3200401 locus and
length, height, and total volume of tumor has been
detected. Thus, more individuals should be in-
cluded in the study in order to make final conclusion
about association between rs3200401 SNP and mor-
phological characteristics of TCCUB tumors.
4. Conclusions
This is the first study investigating the association
between MALAT1 gene rs3200401 SNP and disease-
free survival of BC patients and clinicopathological
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Figure 1. Kaplan-Meier curve for BC-free survival analysis depending on MALAT1 rs3200401
genotype.
Table 3. Analysis of association between MALAT1 rs3200401genotypic and TCCUB-free survival.
Model
Univariate analysis Multivariate analysis
HR 95 % CI P HR 95 % CI P
TT+CT vs CC 0.723 0.492-1.061 0.097 0.782 0.521-1.173 0.235
CT vs TT+CC 1.003 0.663-1.519 0.987 1.003 0.655-1.535 0.991
TT vs CT+CC 0.343 0.148-0.793 0.012 0.413 0.172-0.987 0.047
characteristics in BC. Rs3200401 polymorphism
of MALAT1 gene is associated with disease-free
survival in Ukrainian patients with TCCUB. TC-
CUB occurs later in persons with rs3200401TT-
genotype than in individuals with rs3200401CC-
and rs3200401CT-genotypes.
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